Breaking News Instant updates and real-time market news.

GE

General Electric

$11.10

-0.2 (-1.77%)

, ESIO

Electro Scientific

$14.96

0.2 (1.36%)

09:12
10/30/18
10/30
09:12
10/30/18
09:12

Fly Intel: Pre-market Movers

HIGHER: Electro Scientific (ESIO), up 88% after MKS Instruments (MKSI) announced it was acquiring the company for $30 per share. UP AFTER EARNINGS: Under Armour (UAA), up 15%... KLA-Tencor (KLAC), up 6%... Chegg (CHGG), up 10%. LOWER: GE (GE), down 4.5% after reporting earnings and announcing it is cutting its dividend to 1c from 12c. DOWN AFTER EARNINGS: Cognizant (CTSH), down 7%... Shutterstock (SSTK), down 10%... Pfizer (PFE), down 3%... Masco (MAS), down 5%... Cognex (CGNX), down 9%.

GE

General Electric

$11.10

-0.2 (-1.77%)

ESIO

Electro Scientific

$14.96

0.2 (1.36%)

UAA

Under Armour

$18.20

0.22 (1.22%)

UA

Under Armour

$16.81

0.26 (1.57%)

KLAC

KLA-Tencor

$85.57

-1.63 (-1.87%)

CHGG

Chegg

$22.97

-0.82 (-3.45%)

CTSH

Cognizant

$69.27

-1.25 (-1.77%)

SSTK

Shutterstock

$44.58

-0.22 (-0.49%)

PFE

Pfizer

$43.23

0.64 (1.50%)

MAS

Masco

$27.42

-0.23 (-0.83%)

CGNX

Cognex

$39.57

-1.66 (-4.03%)

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 02

    Nov

  • 07

    Nov

  • 16

    Nov

  • 16

    Nov

  • 27

    Nov

  • 02

    Dec

  • 12

    Dec

  • 03

    Mar

GE General Electric
$11.10

-0.2 (-1.77%)

10/25/18
JPMS
10/25/18
NO CHANGE
Target $10
JPMS
Underweight
General Electric may be double counting up to $18B of assets, says JPMorgan
JPMorgan analyst Stephen Tusa says that after deeper analysis of the company's consolidated financial statements, "there emerges further support" for his view of "how challenged the financial situation" is at General Electric. The company has $100B of net liabilities at present, which after normalizing interest expense, suggests GE is currently generating zero free cash flow into 2019 including Healthcare, and negative $4B including the dividend, Tusa tells investors in a research note titled "Potential Double Counting of Assets Makes Leverage Math More Negative." The analyst thinks investors and rating agencies may be overlooking that a range of $12B-$18B in assets may be "double counted" by GE. "Whether a critical near term liquidity issue or not, this is something that we believe needs to be addressed by new management to move from a low quality levered, financially engineered laggard that we believe deserves a discount, to one that deserves parity, potential actions around which to remedy we see as ultimately dilutive for the equity holder," says Tusa. He keeps an Underweight rating on General Electric with an $18 price target.
10/26/18
GDHS
10/26/18
NO CHANGE
Target $11
GDHS
Underperform
GE may owe billions more on insurance reserves, says Gordon Haskett
General Electric could end up owing billions more dollars for its insurance reserves, on top of the $15B in cash already committed, from an accounting change announced in August. Accounting firms and ratings agencies are apparently just beginning to assess the impact of the Financial Accounting Standards Board issued ASU 2018-12, "Targeted Improvements to the Accounting for Long-Duration Contracts," Gordon Haskett analyst John Inch tells investors in a research note. The ASU 2018-12 changes will apply to insurance companies, including GE, that issue long-duration contracts such as life insurance, disability income, long-term care insurance and annuities, says the analyst. The changes are effective starting at the beginning of 2021. Inch points out that GE lowered its discount rate, or the insurer's expected investment yield, from 6.2% to 5.7% in 2017, which was one of the drivers of its $9.5B pre-tax GAAP charge announced in January. However, after talking with ratings agency, the analyst believes a 5.7% rate is too high and will likely have to come down with the new FASB standard. "At this juncture, while the precise degree of mandated decline remains uncertain, the magnitude is expected to be significant," Inch writes. GE previously disclosed, according to the analyst, that a hypothetical 25 basis point decline in expected investment yield, holding all other assumptions constant, would result in a $1B increase in future policy benefit reserves. Inch has an Underperform rating on General Electric with an $11 price target. The stock in premarket trading is down 16c to $11.64.
10/12/18
FBCO
10/12/18
INITIATION
FBCO
Outperform
EE, MI Sector initiated with Opportunistic View at Credit Suisse
Credit Suisse analyst John Walsh initiated the U.S. Electrical Equipment and Multi-Industry Sector with an Opportunistic View, telling investors in a research note that he believes at this point in the cycle stock appreciation will be driven by earnings growth and capital allocation. He is most positive on energy-related and non-residential end markets while cautious on Fossil Power markets. Specifically, Walsh initiated Allegion (ALLE), Eaton (ETN), Ingersoll-Rand (IR), Lennox (LII), 3M (MMM) and Xylem (XYL) with Outperform ratings, Acuity Brands (AYI), Emerson (EMR), Flowserve (FLS), Fortiv (FTV), GE (GE), Honeywell (HON) and Johnson Controls (JCI) with Neutral ratings and Rockwell Automation (ROK) with an Underperform rating.
10/12/18
GDHS
10/12/18
INITIATION
Target $11
GDHS
Underperform
General Electric initiated with an Underperform at Gordon Haskett
Gordon Haskett analyst John Inch started General Electric with an Underperform rating and $11 price target. GE is going to take a "very long time to turn around, no matter who is at the helm," Inch tells investors in a research note. He believes it is not clear that incremental value is being created by the company's actions to shrink and shuffle its debt. Further, he believes the Power business is facing negative secular pressures that are helping to constrict cash flow.
ESIO Electro Scientific
$14.96

0.2 (1.36%)

01/18/18
LSCM
01/18/18
NO CHANGE
Target $30
LSCM
Buy
Electro Scientific target raised to $30 after preannouncement at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for Electro Scientific to $30 from $27 following last night's positive preannouncement. The company continues to see strong momentum from the flex circuit market, Schmidt tells investors in a research note. He adds, "Simply put, we do not think there is anything more investors could have hoped for from this announcement." The analyst reiterates a Buy rating on the shares.
03/15/18
STFL
03/15/18
INITIATION
Target $36
STFL
Buy
Stifel starts 'turnaround story' Electro Scientific with Buy, $36 target
Stifel analyst Patrick Ho last night initiated Electro Scientific Industries with a Buy rating and $36 price target. Electro is a turnaround story with favorable secular trends that can provide long-term growth, Ho tells investors in a research note. The analyst believes some of the company's growth trends are at an inflection point.
03/14/18
STFL
03/14/18
INITIATION
Target $36
STFL
Buy
Electro Scientific initiated with a Buy at Stifel
Stifel initiated Electro Scientific with a Buy and $36 price target.
03/22/18
LSCM
03/22/18
NO CHANGE
Target $30
LSCM
Buy
Electro Scientific risk/reward opportunity attractive, says Lake Street
After attending the company's analyst day, Lake Street analyst Jaeson Schmidt continues to think investors are presented with an attractive risk/reward opportunity in shares of Electro Scientific Industries. He left the day feeling confident that the company is "positioned on a path of significant long term-growth." The analyst reiterates a Buy rating on the shares with a $30 price target.
UAA Under Armour
$18.20

0.22 (1.22%)

09/21/18
09/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he views the stock's risk/reward as more balanced following the recent underperformance. 2. Acadia (ACAD) upgraded to Overweight from Neutral at Piper Jaffray with analyst Danielle Brill citing the FDA announcement of maintained support for Nuplazid after its review. 3. AT&T (T) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying the stock is trading near all-time low valuations, and at its widest valuation gap to Verizon (VZ), given a mix of EBITDA declines, concerns over the debt load and secular issues impacting the space. 4. Diamond Offshore (DO) upgraded to Buy from Hold at HSBC. 5. Ingersoll-Rand (IR) upgraded to Overweight from Neutral at JPMorgan with analyst Stephen Tusa saying he views the stock's discounted valuation relative to peers as unwarranted following the company's transformation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/18
JEFF
09/27/18
NO CHANGE
JEFF
Under Armour promos down for six straight month, says Jefferies
Jefferies analyst Randal Konik says his firm's September webscrapes illustrate that Under Armour's (UAA) percentage of product on discount is down for the sixth month in a row, while Adidas's (ADDYY) is up seven months in a row. Visits to Finish Line (FINL), Foot Locker (FL), and Under Armour websites reveal the HOVR and Curry 5 are sold out in several sizes and colors, indicating growing brand awareness, Konik tells investors in a research note. He believes Under Armour's promos being down bode well for the company's Q3 results. Further, Nike (NKE) continues to regain share from Adidas in running across the U.S., with strength in Air VaporMax, Air Max 270, and Roshe One, the analyst adds.
09/21/18
JEFF
09/21/18
NO CHANGE
Target $29
JEFF
Buy
Under Armour restructuring news 'should squash' margin doubt, says Jefferies
After the company announced an update to its restructuring plan, Jefferies analyst Randal Konik says he's impressed with Under Armour's "ability to parallel-track operational excellence alongside leading product innovation." Recent successes with the HOVR platform and Project Rock "have quieted bears" who doubted product and brand strength, and yesterday's news "should squash any doubt surrounding the positive trajectory for sustainable operating margin improvement ahead," Konik tells investors in a research note. He reiterates a Buy rating on Under Armour with a $29 price target.
10/26/18
ADAM
10/26/18
NO CHANGE
Target $12
ADAM
Sell
Under Armour top-line concerns have not abated, says Canaccord
Canaccord analyst Camilo Lyon reiterated his Sell rating on Under Armour shares ahead of Q3 results. The analyst said his top-line concerns have not abated and that its slight growth has been driven by accessories, not apparel and footwear. He said Q3 will only serve to highlight the challenges the company continues to face. Lyon has a $12 price target on Under Armour shares.
UA Under Armour
$16.81

0.26 (1.57%)

09/21/18
JPMS
09/21/18
UPGRADE
Target $20
JPMS
Neutral
Under Armour upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Matthew Boss upgraded Under Armour to Neutral and raised his price target for the shares to $20 from $16. The analyst views the stock's risk/reward as more balanced following the recent underperformance. Further, Under Armour's multi-year margin initiative announced yesterday "protect this house," Boss tells investors in a research note.
KLAC KLA-Tencor
$85.57

-1.63 (-1.87%)

10/30/18
UBSW
10/30/18
NO CHANGE
Target $135
UBSW
Buy
KLA-Tencor remains preferred SPE stock at UBS
UBS analyst Timothy Arcuri said KLA-Tencor remains his favorite SPE stock with 2019 still set up as a big WFE share gain for the company. The analyst said the spending mix is set to shift to foundry/logic, and EUV is leading to finite spending dollars being re-allocated from wafer capacity to linear scaling stories like KLA. Arcuri reiterated his Buy rating and lowered his price target to $135 from $140 on KLA-Tencor shares.
10/30/18
KEYB
10/30/18
NO CHANGE
Target $133
KEYB
Overweight
KLA-Tencor price target lowered to $133 from $152 at KeyBanc
KeyBanc analyst Weston Twigg lowered his price target for KLA-Tencor to $133 from $152 following quarterly results to reflect guidance and commentary. The analyst reiterates an Overweight rating on the shares as he views KLA-Tencor as well-positioned in 2019 relative to peers.
10/30/18
COWN
10/30/18
NO CHANGE
Target $120
COWN
Outperform
KLA-Tencor price target lowered to $120 from $148 at Cowen
Cowen analyst Krish Sankar lowered his price target on KLA-Tencor to $120 from $148 despite better than expected Q3 results. The analyst noted the outlook was in-line and he views the export controls on Jinhua as a potential risk, though the company sees limited impact given target export controls. Sankar maintained his Outperform rating on KLA-Tencor shares.
10/30/18
RILY
10/30/18
NO CHANGE
Target $123
RILY
Buy
KLA-Tencor target raised ti $123 on 'strong' print at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for KLA-Tencor to $123 from $120 citing the company's "strong" Q1 results and guidance. The analyst believes KLA-Tencor is navigating the "spending turbulence" and he keeps a Buy rating on the shares.
CHGG Chegg
$22.97

-0.82 (-3.45%)

10/02/18
10/02/18
UPGRADE
Target $34

Buy
Chegg upgraded to Buy as users more concerned about access at Craig-Hallum
As previously reported, Craig-Hallum analyst Alex Fuhrman upgraded Chegg to Buy from Hold saying this social media analysis suggests users are more concerned about account access than security risks. Based on a review of 65 public Twitter posts including the words "Chegg" and "password" since the disclosure of the database breach, it appears that there has not been much blowback, he contends. Fuhrman also raised his price target on the shares to $34 from $27.
10/25/18
SBSH
10/25/18
UPGRADE
Target $28
SBSH
Buy
Citi sees 'attractive entry point' for Chegg, upgrades to Buy
Citi analyst Nithin Pejaver earlier today upgraded Chegg to Buy from Neutral and raised his price target for the shares to $28 from $27. The selloff in the stock following the company's security breach and amid the broader market weakness provides an "attractive entry point," Pejaver told investors in a research note. The analyst expects Chegg's growth to be minimally impacted from the breach and he sees the company's Q3 results meeting expectations.
10/25/18
SBSH
10/25/18
UPGRADE
SBSH
Buy
Chegg upgraded to Buy from Neutral at Citi (pre-open)
10/30/18
FANA
10/30/18
UPGRADE
Target $30
FANA
Outperform
Chegg upgraded to Outperform from Neutral at First Analysis
First Analysis analyst Corey Greendale upgraded Chegg to Outperform with an unchanged price target of $30. The company's "strong" Q3 results and raised guidance, combined with the recent pullback in shares, makes the valuation more compelling, Greendale tells investors in a research note. The analyst sees strong ongoing demand for the Chegg connected learning platform.
CTSH Cognizant
$69.27

-1.25 (-1.77%)

10/19/18
DBAB
10/19/18
NO CHANGE
DBAB
Buy
Cognizant risk/reward looks favorable, says Deutsche Bank
Deutsche Bank analyst Bryan Keane sees a favorable risk/reward on Cognizant Technology Solutions ahead of the company's Q3 results on October 30. The IT spending environment appears healthy and Digital "continues to be a lever for growth with low-20% sustainable in the near-future," Keane tells investors in a research note. He finds the stock attractively valued and keeps a Buy rating on the name.
10/04/18
MOFT
10/04/18
INITIATION
Target $85
MOFT
Neutral
Cognizant initiated with a Neutral at MoffettNathanson
MoffettNathanson initiated Cognizant with a Neutral and $85 price target.
09/18/18
HSBC
09/18/18
UPGRADE
HSBC
Buy
Cognizant upgraded to Buy from Hold at HSBC
09/18/18
09/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cognizant (CTSH) upgraded to Buy from Hold at HSBC. 2. Casey's General Stores (CASY) upgraded to Buy from Neutral at Northcoast with analyst Chuck Cerankosky saying management's plan to enhance earnings growth and shareholder value is well underway as demonstrated by Q1 results. 3. Occidental Petroleum (OXY) upgraded to Buy from Hold at Edward Jones. 4. Vale (VALE) upgraded to Neutral from Underperform at Exane BNP Paribas. 5. Targa Resources (TRGP) upgraded to Outperform from Market Perform at Wells Fargo with analyst Michael Blum saying with the addition of the Grand Prix pipeline, Targa should have a fully integrated suite of natural gas liquids logistics assets from gathering and processing in the Permian to pipeline to fractionation to liquefied petroleum gas export. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SSTK Shutterstock
$44.58

-0.22 (-0.49%)

02/23/18
RHCO
02/23/18
NO CHANGE
Target $47
RHCO
Hold
Shutterstock price target raised to $47 from $38 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Shutterstock to $47 and kept his Hold rating after a "mixed" Q4 performance. Squali notes that while the EBITDA and EPS miss suggest that growth is coming at a higher investment level, the improving growth in Ecommerce and strong performance in Enterprise support a more optimistic view for FY18 and beyond.
08/15/18
DBAB
08/15/18
NO CHANGE
Target $50
DBAB
Hold
Shutterstock price target raised to $50 from $40 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley reiterated his Hold rating on shares of Shutterstock and raised the price target to $50 from $40 following the company's "solid" Q2 results to reflect faster top line growth over the next two years given Enterprise strength and slightly higher multiples in light of the faster growth.
PFE Pfizer
$43.23

0.64 (1.50%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/30/18
UBSW
10/30/18
NO CHANGE
Target $100
UBSW
Buy
Exact Sciences weakness a buying opportunity, says UBS
UBS analyst Daniel Brennan previewed Q3 results for Exact Sciences (EXAS) and said his positive thesis is focused on Q4 where he hopes to see a meaningful increase in testing frequency as the result of its strategic relationship with Pfizer (PFE). He views Q3 as less important to his thesis and would view any weakness following the report as a buying opportunity. Brennan reiterated his Buy rating and $100 price target on Exact Sciences shares.
MAS Masco
$27.42

-0.23 (-0.83%)

10/02/18
GSCO
10/02/18
INITIATION
Target $49
GSCO
Buy
Masco initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Doug Clark started Masco with a Buy rating and $49 price target. The analyst rolled out coverage on the Building Products sector with Neutral rating.
10/02/18
GSCO
10/02/18
INITIATION
Target $49
GSCO
Buy
Masco initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Doug Clark initiated Owens Corning with a Buy and $49 price target saying its diversified portfolio can perform best in a challenging housing market or one facing affordability issues. Further, Clark sees significant value in balance sheet optionality in the form of deployment, and management's diversified approach to buybacks, dividends, and MA&.
10/12/18
10/12/18
DOWNGRADE

Neutral
Masco, Fortune Brands downgraded to Neutral after cabinets survey at Longbow
As previously reported, Longbow analyst Garik Shmois downgraded Masco (MAS) and Fortune Brands (FBHS), both to Neutral from Buy, after the firm's cabinets survey revealed a moderating pace of sales growth. He also cites concerns over the pace of housing growth and subsequent remodeling activity due to rising interest rates. While he maintains a Buy rating on American Woodmark (AMWD), Shmois lowered his price target on the stock to $123 from $156 following the survey.
10/12/18
LBOW
10/12/18
DOWNGRADE
LBOW
Neutral
Masco downgraded to Neutral from Buy at Longbow
CGNX Cognex
$39.57

-1.66 (-4.03%)

10/02/18
DADA
10/02/18
NO CHANGE
Target $57
DADA
Neutral
Cognex offers 'outstanding margin and cash flow profile', says DA Davidson
DA Davidson analyst analyst Matt Summerville says Cognex shares offer an attractive investment opportunity for long-term investors, as the company is "well positioned to achieve strong, double-digit, organic growth - with plentiful secular runway in a growing addressable market". The analyst also cites its "debt-free balance sheet, outstanding gross margins, and strong free cash flow profile". In the near term, Summerville keeps his Neutral rating and $57 price target on Cognex with organic comps "particularly challenging" this year and the toughest compares still to come in Q3. The analyst adds that its valuation at 27.5-times enterprise value to expected FY19 EBITDA relative to 20-30-times historical range is "fair".
10/16/18
10/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Symantec (SYMC) upgraded to Market Perform from Underperform at Cowen with analyst Gregg Moskowitz saying he believes the company continues to face fundamental challenges, though he sees downside risk as very limited at current levels. 2. Las Vegas Sands (LVS) upgraded to Buy from Hold at HSBC. 3. Cognex (CGNX) upgraded to Buy from Hold at Needham with analyst James Ricchiuti saying 2019 should produce a better outcome thanks to Cognex's "robust growth in logistics, emerging 3D machine vision and deep learning technologies." 4. Tapestry (TPR) upgraded to Buy from Hold at Needham with analyst Rick Patel saying after a 14% sell-off in the stock price driven by tariff-related concerns and the slowdown of Asia sales at LVMH (LVMUY), the risk-reward is favorable. 5. Cracker Barrel (CBRL) upgraded to Outperform from Market Perform at Telsey Advisory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/18
NEED
10/16/18
UPGRADE
Target $52
NEED
Buy
Cognex upgraded to Buy at Needham on multiple 2019 catalysts
As reported earlier, Needham analyst James Ricchiuti upgraded Cognex to Buy from Hold with a price target of $52, even though he expects the company's headwinds in the consumer electronics vertical to persist in Q3 and for revenues to fall in the second half overall. The analyst states that 2019 should produce a better outcome thanks to Cognex's "robust growth in logistics, emerging 3D machine vision and deep learning technologies". Ricchiuti acknowledges that the upgrade may be premature, but he expects those factors, along with the "expected steady demand in the U.S. factory automation market and a possible recovery in consumer electronics", to support his constructive view on the stock.
10/16/18
NEED
10/16/18
UPGRADE
NEED
Buy
Cognex upgraded to Buy from Hold at Needham

TODAY'S FREE FLY STORIES

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.